Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament for treating osteonecrosis

A drug and cell scaffold technology, applied in the field of regenerative medicine engineering, can solve the problems of difficult-to-treat cells, limited clinical promotion and application, high viral infection rate, and achieve the effect of broad application prospects.

Active Publication Date: 2008-12-24
北京科润维德生物技术有限责任公司
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the number of adult bone marrow MSCs (BM-MSCs) is extremely small. Studies have found that only 0.001% to 0.01% of mononuclear cells separated by density gradients produce plastic adherent cell clones, and the proliferation and differentiation potential decreases with age. , the virus infection rate is high, and the collection of donor MSCs requires bone marrow aspiration, which limits the source and makes it difficult to obtain the number of cells required for treatment, which limits clinical promotion and application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament for treating osteonecrosis
  • Medicament for treating osteonecrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0058] Embodiment: Treatment experimental scheme of femoral head necrosis

[0059] 1. Applying the principles of tissue engineering, plant the hAMCs-containing cell suspension (obtained in step 13 above) on dematrixed calf bone (biological scaffold) to form hAMCs-dematrixed calf bone composite. Cell concentration is limited by material volume (10 5-6 cells / cm 3 )

[0060] 2. In vivo transplantation of hAMCs-destroyed calf bone composite.

[0061] (1) In conventional osteonecrosis surgery, the necrotic bone is scraped off to expose normal bone tissue and form a bone defect area.

[0062] (2) The hAMCs-destroyed calf bone composite was implanted into the bone defect area by pressing.

[0063] (3) Surgical suture.

[0064] 3. hAMCs-destroyed calf bone composite transplantation for canine femoral head defect

[0065] Dogs were used as model animals to study the effect of human amniotic membrane-derived mesenchymal cells (hAMCs) transplantation in the treatment of femoral hea...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for curing osteonecrosis, belonging to the field of regenerative medicine engineering. Human amniotic mesenchymal cells (hAMCs) are used as cell source for cellular transplantation and tissue organization so as to cure the osteonecrosis and to provide a new way for repairing a damaged osseous tissue and reorganizing tissues. Based on the multi-lineage differentiation potential of the hAMCs, osteocytes, osseous tissues and vascular endotheliums can be differentiated in the human body, thereby completing the processes of osteanagenesis, bone remodeling and vascularization and forming a new osseous tissue integrated with the tissues of the patient.

Description

technical field [0001] The present invention relates to the field of regenerative medicine engineering, in particular to a drug for treating osteonecrosis, which uses human amniotic mesenchymal cells (hAMCs) as a cell source for cell transplantation and tissue construction to treat osteonecrosis. Bone tissue repair and tissue remodeling provide new avenues. Background technique [0002] 1. Osteonecrosis [0003] Osteonecrosis (ON) is divided into two categories: traumatic and non-traumatic. It can affect many joints in the body, among which osteonecrosis of the femoral head (ONFH) is the most common and the most harmful to patients. Femoral head necrosis is an intractable disease with unknown pathogenesis and difficult to cure in the world. Due to its complex etiology and difficult treatment, once the treatment is not timely, it will have a high disability rate of almost 100%, which will seriously affect the quality of life and labor ability of patients. . Studies have sh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/50A61L27/36A61L27/54A61P19/08
Inventor 李荣旗张向利吴亦芳刘艳军曹克富肖静郭丽丽安晶张红霞张伟伟刘佳新
Owner 北京科润维德生物技术有限责任公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com